Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic

Status Completed

Clinical Trial Summary

Investigators will examine safety and efficiency of the cell product of autologous bone marrow-derived mesenchymal stem cells (MSC) for patients with repeated IVF failures and hypoplastic or/and fibrosis process of endometrium

Clinical Trial Description

Sixty patients eligible for the study will be divided to two groups (experimental and control) according to randomization (envelope) procedure in 1:1 ratio.

For patients of the main group bone marrow stem cells will be extracted from the crest of the ilium using standard methodology. After extraction and cultivation final product of autologous bone marrow-derived mesenchymal stem cells will be transplanted to endometrial cavity on menstrual cycle day 5-6. Meanwhile patients will receive three cycles of hormonal replacement therapy (4 mg Progynova (Bayer Pharma, Germany) daily on menstrual cycle day 5-25 in combination with 20 mg Duphaston (Abbott Healthcare Products, B.V., Netherlands) daily from day 15 to day 25. On day 20 of hormonal replacement therapy (HRT) of the last (third) cycle Pipelle-biopsy of endometrium will be performed. Obtained material will be analyzed by immunohistochemistry with the assessment of estrogen and progesterone receptors, VEGFa, GM-CSF, CD133+, CD34 and CD56. Ultrasound characteristics of endometrial quality will be registered on day 9-10 and day 19-21 of every cycle. When morphological and echographic parameters of endometrium are found satisfactory for embryo transfer, the HRT for endometrial preparation for frozen/thawed embryo transfer cycle will be initiated. If acceptable endometrial characteristics are not achieved, patients could be offered to undergo repeated (not more than 3) transplantation of MSC procedures.

Control group will receive three standard cycles of HRT following hysteroscopy before frozen/thawed embryo transfer. If endometrial characteristics are found unsatisfactory, gestational surrogacy might be offered. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03166189
Study type	Interventional
Source	D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
Contact
Status	Completed
Phase	Phase 2
Start date	December 20, 2017
Completion date	December 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05969574` - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting	`NCT05358483` - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting	`NCT05969795` - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support	Phase 1
Recruiting	`NCT06051201` - Innovation for Small-scale Experiments: ReceptIVFity Test	N/A
Completed	`NCT03177538` - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders	Phase 4
Completed	`NCT03638856` - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy	N/A
Completed	`NCT04052464` - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn	`NCT04753736` - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC	N/A
Completed	`NCT03349905` - Deferred Versus Fresh Embryo Transfers	N/A
Completed	`NCT05076981` - Progesterone Levels During Ovulation and Luteal Phase
Completed	`NCT04096027` - Cabergoline Before or After Oocyte Collection for Follicular Resolution	Phase 4
Recruiting	`NCT05980091` - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.	Phase 1
Terminated	`NCT01933633` - Improved Fertility After Exercise in Overweight/Obese Women	N/A
Terminated	`NCT01202643` - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF	Phase 1/Phase 2
Completed	`NCT01202656` - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)	Phase 1/Phase 2
Completed	`NCT01408615` - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation	`NCT05698550` - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET	Phase 3
Not yet recruiting	`NCT03910582` - Personalized FET in RIF Patients With Displaced Dating	N/A
Completed	`NCT05440019` - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed	`NCT05130125` - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms